SCHEMBL11924148

SCHEMBL11924148

Cn1c(=O)n(-c2nnc(C(=O)Nc3cnccc3N3CCNCC3)o2)c2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 1/20 0.47
▸ PIM3 Q86V86 1/20 0.47
▸ CHEK1 O14757 14/20 0.47
▸ BRPF1 P55201 2/20 0.47
▸ PRKCA P17252 1/20 0.43
▸ GSK3B P49841 1/20 0.43
▸ PRKCQ Q04759 1/20 0.43
▸ PIM2 Q9P1W9 1/20 0.43
▸ ATR Q13535 2/20 0.41
▸ JAK2 O60674 1/20 0.40
▸ ROCK2 O75116 1/20 0.40
▸ IGF1R P08069 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ AKT1 P31749 1/20 0.40
▸ RPS6KA3 P51812 1/20 0.40
▸ NEK2 P51955 1/20 0.40
▸ STK3 Q13188 1/20 0.40
▸ CAMK4 Q16566 1/20 0.40
▸ TSSK2 Q96PF2 1/20 0.40
▸ IRAK4 Q9NWZ3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11924170 0.87 CHEK1 (0.45) PIM1PIM3CHEK1BRPF1PRKCA
SCHEMBL11923995 0.86 PIM1 (0.49) PIM1PIM3CHEK1BRPF1PRKCA
SCHEMBL11924067 0.86 PIM1 (0.49) PIM1PIM3CHEK1BRPF1PRKCA
SCHEMBL11924157 0.86 CHEK1 (0.42) PIM1PIM3CHEK1BRPF1PRKCA
SCHEMBL11924168 0.85 PIM1 (0.47) PIM1PIM3CHEK1BRPF1PRKCA
SCHEMBL11923852 0.84 PIM1 (0.48) PIM1PIM3CHEK1BRPF1PRKCA
SCHEMBL11924154 0.82 PIM1 (0.55) PIM1PIM3CHEK1PRKCAGSK3B
SCHEMBL11924211 0.81 CHEK1 (0.51) PIM1PIM3CHEK1BRPF1PRKCA
SCHEMBL11924172 0.81 CHEK1 (0.65) PIM1PIM3CHEK1PRKCAGSK3B
SCHEMBL13027394 0.80 CHEK1 (0.55) PIM1PIM3CHEK1PRKCAGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8669259-B2 Heterocyclic amide compounds as protein kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2014-03-11 — — US disclosed
US-8669259-B2 Heterocyclic amide compounds as protein kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2014-03-11 — — US disclosed
US-20120208826-A1 HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2012-08-16 — — US disclosed
US-20120208826-A1 HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2012-08-16 — — US disclosed
WO-2011025706-A2 HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2011-03-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208826-A1 HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS CDK1, MTOR, GAK PIM1 641/4885PIM3 951/4885CHEK1 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback